Natera CEO Sold $545,000 in Company Stock
The transaction reduces the chief executive's direct stake to 0.06% of the company's equity.
Updated on Sept. 18, 2026 in Public Companies
Live Poll
Do you trust routine insider stock sales as a neutral indicator of a company's health?
On September 1, 2026, Natera CEO Steven Leonard Chapman sold 1,698 shares of common stock at a weighted average price of $320.99 per share. The transaction, which totaled $545,000, was completed under a pre-established trading plan.
Why it matters
The sale allows leadership to realize equity gains through structured mechanisms, providing transparency while maintaining ongoing investment in the company. For operators, such filings offer a look at how executive compensation and liquidity strategies are executed at the firm's $52.1 billion valuation.
Natera, which reported $2.7 billion in TTM revenue against $192.3 million in net losses, retains a market capitalization of $52.1 billion. The CEO now holds 98,199 shares, maintaining a 0.06% direct ownership stake.
The players
Natera
A diagnostics company focused on genetic testing and precision medicine with a $52.1 billion market valuation.
Steven Leonard Chapman
The Chief Executive Officer of Natera who holds a 0.06% direct equity stake in the firm.
The details
The sale was executed under a Rule 10b5-1 trading plan, a mechanism that allows company insiders to schedule trades in advance to avoid potential conflicts regarding material non-public information. This specific plan was originally adopted in December 2023 and underwent an amendment in March 2026. The transaction represents a routine exercise of equity management rather than a discretionary divestment.
Timeline
December 2023: Rule 10b5-1 trading plan was adopted.
March 2026: The existing trading plan was amended.
September 1, 2026: The CEO completed the sale of 1,698 shares.
Market Landscape
This sale follows the standard disclosure pattern established by SEC Rule 10b5-1, which governs how corporate insiders manage stock sales to remain compliant with insider trading regulations. The reliance on pre-set trading plans remains a common strategy for executives at publicly traded firms seeking to manage personal liquidity while minimizing regulatory exposure.
Operators should view this sale as a standard component of institutional equity compensation rather than a signal of company performance. Investors and managers should continue to monitor analyst price targets, which currently range from $280 to $435, to gauge the broader market sentiment for Natera.
The takeaway
Executive stock sales executed under Rule 10b5-1 plans provide a predictable mechanism for liquidity that should not be interpreted as an ad-hoc signal on firm health. Keep a record of your company's own insider trading policy and ensure all officers understand the specific disclosure requirements for equity transactions.
Further reading
For more on how major firms manage equity and ownership disclosures, see our Public Companies section.
Live Poll
Do you trust routine insider stock sales as a neutral indicator of a company's health?
